NCT02630199View on ClinicalTrials.gov

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

April 19, 2021

Conditions
Refractory Cancer
Interventions
DRUG

AZD6738

The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.

DRUG

Paclitaxel

Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks

Trial Locations (1)

135-720

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02630199 - Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | Biotech Hunter | Biotech Hunter